Excerpts

A dose of 1 μM AB3 (mean ± SEM, 2.10 ± 0.02, p = 0.822) also showed a trend toward increased SSTR2 expression, but this increase was not found to be significant.

Discussion Our initial analysis revealed slightly worsened DFS and DSS in BRCA1/BRCA2 mutation carriers compared with non-carriers; however, the difference was less than 10% at 10 years and marginally significant for DSS only (HR = 1.65 95% CI 1.01–2.70).

Overall, survival analyses showed a trend toward better OS for HPV-positive (67% survival) compared to HPV-negative (27% survival) patients but that did not reach statistical significance ( p = 0.12), most probably due to the small number of HPV-positive cases ( Figure 4 A). 2.3. p16Ink4a Protein Immunohistochemical (IHC) Staining In view of the small number of HPV-positive HNSCC patients found in this cohort, and the limited amount of pathological materials available, a subset of 50 representative specimens were processed for p16 protein IHC staining.

The relationship between HPV and OS after the treatment showed a clear trend toward a longer survival of HPV-positive patients ( Figure 4 A) as described elsewhere [ 40 ].

III-IV, p = 0.019), more frequent mutations in the miR-887 gene in males ( p = 0.045), and a borderline significant correlation of miR-664b gene mutations with lower cigarette-per-day-smoking in LUAD.

Due to this highly significant effect, trial accrual was stopped prematurely prior to the first preplanned interim efficacy analysis [ 18 ].

The two ratios that were known for this patient were higher than the cut-off values and, thus, showed a trend to be classified as an HNSCC-CP.

More importantly, tumors with a high expression of AGR2 showed a significant trend of a progressive decrease in patients’ survival [ 43 ].

Likewise, in multinomial logistic regression analysis taking ImA as a reference group, PLR counts were still significantly associated with the Im-Clus (age-adjusted OR 1.20, 95% confidence interval (CI) 1.00–1.44 for ImB and 1.24, 95% CI 1.04–1.49 for ImC) and a tendency towards significance was observed for platelets (age-adjusted OR 1.08, 95% CI 0.98–1.19 for ImB and 1.03, 95% CI 0.93–1.14 for ImC) ( Table 1 ).

In a retrospective analysis that included 58 patients with NSCLC treated with anti-PD-1/PD-L1 therapies, EGFR -mutant or ALK -positive patients showed a statistically significant shorter PFS and borderline significant lower ORR compared with EGFR wild-type and ALK -negative/unknown patients [ 42 ].

Quantification of luminescence derived from the metastases revealed a dramatic and significant reduction in metastatic burden in mice provided SLC-0111 compared to animals administered sunitinb or vehicle and showed a trend toward reduced metastasis in animals administered combination therapy ( Figure 1 e).

Patients presenting non-metastatic advanced HCC with vascular invasion ( n = 1136) showed a trend towards significant risk reduction with an HR of 0.78 (95% CI, 0.59–1.02) ( Figure 3 ).

Nevertheless, it is interesting to note that WNT11 mRNA expression also showed a trend for association with increased mortality ( Figure 1 d), which was significant only when combining expression with FZD6, RYK and/or PTK7 ( Figure 1 e).

We found increased expression of FZD6, FZD7, RYK, and PTK7 in tumors, as well as a highly significant increase in FZD7 in tumor-adjacent cells ( Table 2 and Figure S1b ).

However, NANOG gene expression was upregulated in both NTERA-2 CisR and NCCIT CisR cell lines at borderline significance levels.

In our RNA expression analyses, the tumors from bGH transgenic mice showed a nonsignificant trend towards an increase in MITF levels compared to WT, in both sexes ( Figure 6 A,B).

The presence of ascites before surgery ( p = 0.083) and macroscopic residual tumor after surgery ( p = 0.067) showed a trend to reduced platinum-sensitivity.

The results indicate that systemic injection of siRNA-packaged OMVs caused targeted gene silencing and induced highly significant tumor growth regression in an animal model.

However, yatein treatment showed an increasing trend of Cdc2 phosphorylation in both cell types.

Slightly significant reduction in pure-tone average (PTA) and in the speech discrimination score (SDS) was measured, which, however, were functionally not relevant ( Table 1 ).

We have recently identified SF3B1 on chromosome 2 as a Copy-number alterations Yielding Cancer Liabilities Owing to Partial losS (CYCLOPS) gene with a highly significant positive correlation to hypoxia-inducible factor-1α (HIF1α) [ 26 ].

Although a slight increase of marginal significance in the total number of tumor GFP + cells was detected for co-cultures with TGF-β treated NIH3T3 in the microscale platform ( Figure 4 A.2), the overall effect on tumor growth was of similar magnitude regardless of the culture modality for both WT and TGF-β co-cultures.

In contrast, CRT ( n = 241) seemed to provide only a slight trend towards an OS advantage in R1-resected pts, emerging as a positive difference in median values of 3.5 months, as well as non-significant HR of 0.72 and 2-y and 5-y rates (30% vs. 19% with observation, and 18% vs. 8%, respectively).

In addition, an increasing trend was present between doxorubicin intensity and injected dose similar to that observed in the whole tumor slices ( Figure 3 B).

Based on high (H) or low (L) BAP1 gene expression levels, we investigated the survival difference within these two groups and found that in LGG, HNSC and PRAD, the survival difference between BAP1 high- and low- expression patients was slightly significant (–log­ 10 ( p -value) >1.2) ( Figure 4 A, B).